Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'

The Swiss company posted first-quarter sales of $13.1 billion, below the $13.5 billion expected by analysts polled by FactSet and reflecting a 1% decline year-on-year. Sales declined by 5% on a constant currency basis. Earnings per share came in at $1.65, down 10% year-on-year. The miss was driven by faster-than-expected generic erosion of the company's best-selling medicines Entresto, Promacta, and Tasigna, which each missed by between 7% and 17%, according to Citi analysts. The sales decline was only partially offset by the growth of newer medicines like breast cancer treatment Kisqali and multiple sclerosis drug Kesimpta.Sales of heart drug Entresto fell 42% after its U.S. patent expired. It faces loss of exclusivities in Europe later this year. "We guided to a first half that was going to be challenging — we knew these generics were coming. It's actually the biggest loss of exclusivity in Novartis' history," Narasimhan said.Novartis has guided for a pickup in growth over the second half of the year.

This excerpt is published under fair use for community discussion. Read the full article at CNBC.